journal article·2023-04-28Open access

Utilization of Stimuli-Responsive Biomaterials in the Formulation of Cancer Vaccines

Arun Kumar Singh, Rishabha Malviya, Bhupendra Prajapati, Sudarshan Singh, Priyanshi Goyal

Abstract

Immunology research has focused on developing cancer vaccines to increase the number of tumor-specific effector cells and their ability to fight cancer over the last few decades. There is a lack of professional success in vaccines compared to checkpoint blockade and adoptive T-cell treatment. The vaccine’s inadequate delivery method and antigen selection are most likely to blame for the poor results. Antigen-specific vaccines have recently shown promising results in preclinical and early clinical investigations. To target particular cells and trigger the best immune response possible against malignancies, it is necessary to design a highly efficient and secure delivery method for cancer vaccines; however, enormous challenges must be overcome. Current research is focused on developing stimulus-responsive biomaterials, which are a subset of the range of levels of materials, to enhance therapeutic efficacy and safety and better regulate the transport and distribution of cancer immunotherapy in vivo. A concise analysis of current developments in the area of biomaterials that respond to stimuli has been provided in brief research. Current and anticipated future challenges and opportunities in the sector are also highlighted.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida 203201, India

Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva 384012, India

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand

References (88)

Show source-provided references
1. Therapeutic vaccines for cancer: An overview of clinical trials10.1038/nrclinonc.2014.111 ↗
2. PROVENGE (sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine10.1158/1078-0432.CCR-10-3126 ↗
3. Personalized vaccines for cancer immunotherapy10.1126/science.aar7112 ↗
4. Efficient nanovaccine delivery in cancer immunotherapy10.1021/acsnano.7b00978 ↗
5. Drug delivery in cancer therapy, Quo Vadis?10.1021/acs.molpharmaceut.8b00037 ↗
6. Drug delivery and targeting
7. Advances in biomaterials for drug delivery10.1002/adma.201705328 ↗
8. A powerful CD8+ T-cell stimulating D-tetra-peptide hydrogel as a very promising vaccine adjuvant10.1002/adma.201601776 ↗
9. Synthetic nanoparticles for vaccines and immunotherapy10.1021/acs.chemrev.5b00109 ↗
10. Engineering new approaches to cancer vaccines10.1158/2326-6066.CIR-15-0112 ↗
11. Neoantigen vaccine delivery for personalized anticancer immunotherapy10.3389/fimmu.2018.01499 ↗
12. Bioresponsive materials10.1038/natrevmats.2016.75 ↗
13. Controlled drug delivery vehicles for cancer treatment and their performance10.1038/s41392-017-0004-3 ↗
14. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
15. Polymeric micelles with stimuli-triggering systems for advanced cancer drug targeting10.3109/1061186X.2014.936872 ↗
16. Cancer vaccines
17. Vaccines for established cancer: Overcoming the challenges posed by immune evasion10.1038/nrc.2016.16 ↗
18. Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo10.1016/j.it.2017.04.002 ↗
19. The urgent need to recover MHC class I in cancers for effective immunotherapy10.1016/j.coi.2015.12.007 ↗
20. Towards a systems understanding of MHC class I and MHC class II antigen presentation10.1038/nri3084 ↗
21. The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors10.1038/ni.1863 ↗
22. Biomaterials for nanoparticle vaccine delivery systems10.1007/s11095-014-1419-y ↗
23. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration10.1023/A:1015880819328 ↗
24. Targeting the lymphatics using dendritic polymers (dendrimers)10.1016/j.addr.2011.05.016 ↗
25. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles10.1016/j.jconrel.2006.01.006 ↗
26. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma10.1021/acsnano.5b01042 ↗
27. Tailoring biomaterials for cancer immunotherapy: Emerging trends and future outlook10.1002/adma.201606036 ↗
28. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity10.1038/nbt.3371 ↗
29. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles10.1073/pnas.0509541102 ↗
30. A simple and powerful co-delivery system based on pH-responsive metal-organic frameworks for enhanced cancer immunotherapy10.1016/j.biomaterials.2017.01.017 ↗
31. Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy10.1021/bc100204m ↗
32. pHresponsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides10.1021/nn305466z ↗
33. The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy10.1016/j.biomaterials.2013.04.007 ↗
34. pH-responsive poly(D,L-lactic-coglycolic acid) nanoparticles with rapid antigen release behavior promote immune response10.1021/nn5066793 ↗
35. A STING-activating nanovaccine for cancer immunotherapy10.1038/nnano.2017.52 ↗
36. Enhanced class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide10.1021/acs.molpharmaceut.7b00760 ↗
37. Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization10.1016/j.actbio.2012.06.007 ↗
38. Complex consisting of β-glucan and antigenic peptides with cleavage site for glutathione and aminopeptidases induces potent cytotoxic T lymphocytes10.1021/acs.bioconjchem.7b00159 ↗
39. Intracellular cleavable CpG oligodeoxynucleotideantigen conjugate enhances anti-tumor immunity10.1016/j.ymthe.2016.10.001 ↗
40. Reduction-responsive codelivery system based on a metal–organic framework for eliciting potent cellular immune response10.1021/acsami.8b01680 ↗
41. “Minimalist” nanovaccine constituted from near whole antigen for cancer immunotherapy10.1021/acsnano.8b00558 ↗
42. Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen10.1016/j.jconrel.2013.11.017 ↗
43. Cytosolic delivery of liposomal vaccines by means of the concomitant photosensitization of phagosomes10.1021/acs.molpharmaceut.5b00394 ↗
44. A light responsive nanoparticle-based delivery system using pheophorbide A graft polyethylenimine for dendritic cell-based cancer immunotherapy10.1021/acs.molpharmaceut.7b00015 ↗
45. Photothermally controlled MHC class I restricted CD8+ T-cell responses elicited by hyaluronic acid decorated gold nanoparticles as a vaccine for cancer immunotherapy10.1002/adhm.201701439 ↗
46. Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound-responsive and mannose-modified gene carrier10.1021/mp100369n ↗
47. Enhancement of the anti-tumor effect of DNA vaccination using an ultrasoundresponsive mannose-modified gene carrier in combination with doxorubicin-encapsulated PEGylated liposomes10.1016/j.ijpharm.2014.09.005 ↗
48. Exploiting lymphatic transport and complement activation in nanoparticle vaccines10.1038/nbt1332 ↗
49. Structure-based programming of lymph-node targeting in molecular vaccines10.1038/nature12978 ↗
50. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles10.1073/pnas.1105200108 ↗
51. Gene transfection in complex media using PCBMAEE-PCBMA copolymer with both hydrolytic and zwitterionic blocks10.1016/j.biomaterials.2014.05.066 ↗
52. Quantitative measurement of intraorganelle pH in the endosomal-lysosomal pathway in neurons by using ratiometric imaging with pyranine10.1073/pnas.92.8.3156 ↗
53. A novel strategy for encapsulation and release of proteins: Hydrogels and microgels with acid-labile acetal cross-linkers10.1021/ja026925r ↗
54. A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels10.1073/pnas.0930644100 ↗
55. T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: The effect of particle size10.1021/bc800338n ↗
56. Acid-degradable polyurethane particles for protein-based vaccines: Biological evaluation and in vitro analysis of particle degradation products10.1021/mp800068x ↗
57. Antigen-loaded pH-sensitive hydrogel microparticles are taken up by dendritic cells with no requirement for targeting antibodies10.1039/c2ib20109g ↗
58. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation10.1073/pnas.1600816113 ↗
59. Transiently thermoresponsive acetal polymers for safe and effective administration of amphotericin B as a vaccine adjuvant10.1021/acs.bioconjchem.7b00641 ↗
60. Toll-dependent selection of microbial antigens for presentation by dendritic cells10.1038/nature04596 ↗
61. Acid-labile traceless click linker for protein transduction10.1021/ja302705v ↗
62. Hydrogels: From controlled release to pH-responsive drug delivery10.1016/S1359-6446(02)02255-9 ↗
63. Ovalbumin-coated pH-sensitive microneedle arrays effectively induce ovalbuminspecific antibody and T-cell responses in mice10.1016/j.ejpb.2014.05.003 ↗
64. pH sensitization of phospholipid vesicles via complexation with synthetic poly(carboxylic acid)10.1111/j.1749-6632.1985.tb18404.x ↗
65. Antigen delivery with poly(propylacrylic acid)conjugation enhances MHC-1 presentation and T-cell activation10.1021/bc800317a ↗
66. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+ T cell responses10.1016/j.jconrel.2014.03.041 ↗
67. Carboxylated hyperbranched poly(glycidol)s for preparation of pH-sensitive liposomes10.1016/j.jconrel.2010.03.001 ↗
68. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice10.1080/1061186X.2017.1387788 ↗
69. Design of pH-sensitive polymer-modified liposomes for antigen delivery and their application in cancer immunotherapy10.1038/pj.2016.31 ↗
70. Yuba, E., Sakaguchi, N., Kanda, Y., Miyazaki, M., and Koiwai, K. (2017). pH-responsive micelle-based cytoplasmic delivery system for induction of cellular immunity. Vaccines, 5.10.3390/vaccines5040041 ↗
71. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo10.1016/j.jconrel.2009.06.008 ↗
72. GALA: A designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery10.1016/j.addr.2003.10.041 ↗
73. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses10.1038/nmat2960 ↗
74. Endolysosomalescape nanovaccines through adjuvant-induced tumor antigen assembly for enhanced effector CD8+ T cell activation10.1002/smll.201703539 ↗
75. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine10.1073/pnas.92.16.7297 ↗
76. Ultra-pH-sensitive nanoprobe library with broad pH tunability and fluorescence emissions10.1021/ja5053158 ↗
77. Redox characteristics of the eukaryotic cytosol10.1016/j.bbamcr.2007.10.013 ↗
78. Chemisorbed poly(propylene sulphide)-based copolymers resist biomolecular interactions10.1038/nmat851 ↗
79. Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds10.1039/C6NR05583D ↗
80. Redox compartmentalization in eukaryotic cells10.1016/j.bbagen.2008.01.011 ↗
81. Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells10.1016/j.jconrel.2014.11.032 ↗
82. Shedding light onto live molecular targets10.1038/nm0103-123 ↗
83. Enhanced MHC-I antigen presentation from the delivery of ovalbumin by lightfacilitated biodegradable poly(ester amide)s nanoparticles10.1039/C7TB03233A ↗
84. Tumor marker-responsive behavior of gels prepared by biomolecular imprinting10.1073/pnas.0506786103 ↗
85. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy10.1016/j.biomaterials.2010.11.028 ↗
86. Enzyme-responsive nanomaterials for controlled drug delivery10.1039/C4NR04249B ↗
87. Conductive polymers: Towards a smart biomaterial for tissue engineering10.1016/j.actbio.2014.02.015 ↗
88. Mechanical force-triggered drug delivery10.1021/acs.chemrev.6b00369 ↗